Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM03

Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Chemotherapy

Presenters: Nick Crozier, PharmD, BCPS, Pharmacy Director, UNM Cancer Center, UNM Comprehensive Cancer Center; Ronald Kittson, PharmD, Clinical Pharmacy Supervisor, UNM Comprehensive Cancer Center

Co-Authors: Lisa Anselmo, PharmD, BCOP, Clinical Pharmacy Director, Pharmacy, UNM Hospitals; Branda Chalenunphonh, Student Pharmacist, UNM College of Pharmacy

Background: Body surface area (BSA) is used to calculate individual doses for chemotherapeutic agents.1 Default BSA calculation equations vary between e-prescribing platforms. At the University of New Mexico Comprehensive Cancer Center (UNMCCC) our e-prescribing platform used DuBois & DuBois; however, because of the complexity of the DuBois & DuBois equation, our nurses and pharmacists use Mosteller. To improve safety, we changed our e-prescribing platform calculation to Mosteller.

Objective: To determine whether switching BSA calculation from DuBois & DuBois to Mosteller results in clinical differences in dose or in outcomes for patients receiving chemotherapy.

Methods: The UNMCCC switched from the DuBois & DuBois to Mosteller BSA calculation on July 6, 2020. We collected data that included changes in BSA, therapeutic dose changes, and adverse event reporting. We extracted data for all chemotherapeutic agents that required BSA dosing between May 1, 2020, and August 10, 2020, to compare chemotherapy doses given to patients before and after the calculation switch date. Patients who received the same chemotherapeutic agent as part of the same regimen at least once before and after July 6, 2020, were included. Only the latest chemotherapy dose before July 6, 2020, and the earliest dose after July 6, 2020, were evaluated. We used each patient’s most recent height and weight before July 6, 2020, to calculate predicted Mosteller BSA. Finally, we examined individually all dose increases by ≥5%, for safety.

Results: A total of 227 patients who received a total of 367 doses were evaluated. In all, 234 doses had no change, 10 doses increased by 5% to 10%, and 6 doses increased by >10%. We calculated the predicted patient BSA change corresponding to 330 of the doses. Of the predicted BSA changes, 23% were expected to increase by ≥2.5% and 6.67% were expected to increase by 5% to 10%. Predicted BSA changes correlated poorly with dose changes (r2 = 0.0058). Most doses remained unchanged because of physician manual calculations, use of previous BSA option, and pharmacist dose adjustment and rounding. Dose increases of >10% were caused by changes in the patient’s weight and provider’s chemotherapy regimen adjustment. There were no adverse events reported or safety concerns.

Conclusion: Switching the e-prescribing platform BSA calculation from DuBois & DuBois to Mosteller resulted in an overall increase in our patients’ calculated BSA, without significant clinical impact on the patients’ dose or outcome. The change from DuBois & DuBois to Mosteller can be safely made in clinical practice for patients receiving active chemotherapy.

  1. Fancher KM, Sacco AJ, Gwin RC, et al. Comparison of two different formulas for body surface area in adults at extremes of height and weight. J Oncol Pharm Pract. 2016;22:690-695.
Related Items
Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers
Operation Angel on the Line: Oncology Pharmacist and Pharmacy Students Piloting a New Oral Chemotherapy Telehealth Clinic During the COVID-19 Pandemic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, COVID-19
Integration of a Clinical Pharmacist in a Phase 1 Clinical Trial Program
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials
Feasibility and Perceived Benefit of an Oral Chemotherapy Pharmacy Monitoring Program to Assess Symptom Burden and Medication Adherence in Patients with Cancer
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Chemotherapy, Oncology Pharmacy Protocols
The Incidence of Coring Between the Traditional Syringe and Needle Compounding Technique and Closed-System Transfer Devices
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Infusion Issues
Impact of Drug Repository Program in a Rural Oncology Clinic
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Oncology Pharmacy Programs
Evaluation of Treatment Abandonment and Delay with Anticancer Agents at an Outpatient Community Hospital Cancer Center Oral Chemotherapy Clinic: A Retrospective Cohort Analysis
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Chemotherapy, Oncology Pharmacy Programs
Evaluation of the Relationship between Hypoalbuminemia and Oral Anticancer Drug-Related Adverse Events in Adults with Solid Tumor Malignancies
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events
Worldwide Influenza and Pneumococcal Vaccination Rates in Patients with Multiple Myeloma, and the Impact of Vaccination on Infection, Hospitalization, and Death
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma, Vaccinations
The Incidence of Arterial and Venous Thromboembolism in Patients with Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Who Are Treated with Ponatinib
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Leukemia, Thromboembolism
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.